New Two-Drug attack on Tough-to-Treat cancers
Disease control
Recruiting now
This study is testing a new oral drug, FC084CSA, given alongside an existing immunotherapy called tislelizumab. The goal is to find a safe and effective dose for treating patients with advanced solid tumors that have worsened despite standard therapies. The trial will first find …
Phase: PHASE1, PHASE2 • Sponsor: FindCure Biosciences (ZhongShan) Co., Ltd. • Aim: Disease control
Last updated Mar 27, 2026 12:38 UTC